Linked Life Data

16678871

Source:http://linkedlifedata.com/resource/pubmed/id/16678871

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2006-10-3
pubmed:abstractText
A male patient with psoriatic arthritis and visceral Leishmania infantum infection was treated with oral miltefosine 50 mg three times a day for 4 weeks at the Academic Medical Center, Amsterdam, The Netherlands. Miltefosine plasma concentrations were measured with liquid chromatography/mass spectrometry. The parasite load was followed by quantitative nucleic acid sequence-based amplification (QT-NASBA) assay in blood. Miltefosine elicited a prompt therapeutic effect. After an initial worsening of symptoms and an increase of QT-NASBA values during the first week, recovery was rapidly achieved. QT-NASBA values declined exponentially and were negative after 6 weeks. Miltefosine plasma concentrations continued to accumulate during the 4 weeks of treatment. The terminal elimination half-life was 14.8 days.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0035-9203
pubmed:author
pubmed:issnType
Print
pubmed:volume
100
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1183-6
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Quantification of the response to miltefosine treatment for visceral leishmaniasis by QT-NASBA.
pubmed:affiliation
Academic Medical Center, Division of Infectious Diseases, Tropical Medicine & AIDS, Meibergdreef 9, Amsterdam, The Netherlands. p.j.devries@amc.uva.nl
pubmed:publicationType
Journal Article, Case Reports